Benzinga · Aug 7, 2026
Truist Securities Maintains Hold on Organogenesis Holdings, Lowers Price Target to $2
Truist Securities analyst Ravi Misra maintains Organogenesis Holdings (NASDAQ:ORGO) with a Hold and lowers the price target from $3 to $2.
OR
NASDAQ · ORGO
Organogenesis Holdings Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$1.72
Up+$0.07 (+4.07%)
Updated Aug 18, 2026, 10:20 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 607.66M
- P/E ratio
- -69.15
- Dividend yield
- 0.00%
- 52-week range
- $1.54 – $2.82
- Volume
- 655.77K
- Avg. volume
- 1.55M
Price performance
ORGO price history
1M range · 0 trading sessions · Daily adjusted prices
ORGO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest ORGO news
The latest Smart Investors Daily articles mentioning ORGO.
Stock researchCompany · Overview
ORGO research
Overview
Company profile and research snapshot.
Company profile
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | Truist Securities | Hold | — |
| May 28, 2026 | Truist Securities | Hold | — |
| Mar 26, 2026 | BTIG | Buy | — |
| Feb 27, 2026 | BTIG | Buy | — |
| Dec 26, 2025 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 7, 2026
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call August 6, 2026 5:00 PM EDTCompany ParticipantsGary Gillheeney - President, CEO, Chair of the...
ChartMill · Aug 7, 2026
Organogenesis Holdings (NASDAQ:ORGO) Plunges 17% as Q2 Revenue and EPS Miss Estimates
Organogenesis (ORGO) shares fell 17% after Q2 2026 revenue and EPS missed badly: $43.8M vs $55.3M expected, with wider-than-expected loss.
Benzinga · Aug 6, 2026
Organogenesis Holdings Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $179.000M-$215.000M vs $282.850M Est
Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $270.000 million-$310.000 million to $179.000 million-$215.000 million vs $282.850 million estimate.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
